A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

Nature Structural and Molecular Biology

Volumn 18, Issue 6, 2011, Pages 721-727

  Toledo, Luis I ^a   Murga, Matilde ^a   Zur, Rafal ^a   Soria, Rebeca ^a   Rodriguez, Antonio ^a   Martinez, Sonia ^a   Oyarzabal, Julen ^a,b   Pastor, Joaquin ^a   Bischoff, James R ^a   Fernandez Capetillo, Oscar ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; CAFFEINE; CYCLIN E; DNA DEPENDENT PROTEIN KINASE; ETP 46046; ETP 46464; NU 7026; PROTEIN P53; RAPAMYCIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; GENE MUTATION; GENE REPLICATION; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL SURVIVAL; CELLS, CULTURED; CHROMOSOME BREAKAGE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FIBROBLASTS; IMIDAZOLES; MICE; PROTEIN-SERINE-THREONINE KINASES; QUINOLINES; TUMOR SUPPRESSOR PROTEIN P53;

ATAXIA TELANGIECTASIA;

EID: 79958865837     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2076     Document Type: Article

References (50)

1. Lempiäinen, H. & Halazonetis, T.D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 28, 3067-3073 (2009).
2. López-Contreras, A.J. & Fernandez-Capetillo, O. The ATR barrier to replication-born DNA damage. DNA Repair (Amst.) 9, 1249-1255 (2010).
3. Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005). (Pubitemid 40558993)
4. Gorgoulis, V.G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907-913 (2005). (Pubitemid 40559004)
5. Halazonetis, T.D., Gorgoulis, V.G. & Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355 (2008). (Pubitemid 351354863)
6. Bartkova, J. et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006). (Pubitemid 44864442)
7. Di Micco, R. et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444, 638-642 (2006). (Pubitemid 44864443)
8. Mallette, F.A., Gaumont-Leclerc, M.F. & Ferbeyre, G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 21, 43-48 (2007). (Pubitemid 46089705)
9. Cimprich, K.A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616-627 (2008). (Pubitemid 352032926)
10. Toledo, L.I., Murga, M., Gutierrez-Martinez, P., Soria, R. & Fernandez-Capetillo, O. ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev. 22, 297-302 (2008). (Pubitemid 351214271)
11. Kumagai, A., Lee, J., Yoo, H.Y. & Dunphy, W.G. TopBP1 activates the ATR-ATRIP complex. Cell 124, 943-955 (2006). (Pubitemid 43344235)
12. Link, W. et al. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J. Biol. Chem. 284, 28392-28400 (2009).
13. Cliby, W.A. et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 17, 159-169 (1998). (Pubitemid 28041057)
14. Bakkenist, C.J. & Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003). (Pubitemid 36168436)
15. Cuadrado, M. et al. ATM regulates ATR chromatin loading in response to DNA doublestrand breaks. J. Exp. Med. 203, 297-303 (2006). (Pubitemid 43290838)
16. Jazayeri, A. et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37-45 (2006). (Pubitemid 43064795)
17. Matsuoka, S., Huang, M. & Elledge, S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897 (1998). (Pubitemid 28555269)
18. Chen, B.P. et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J. Biol. Chem. 280, 14709-14715 (2005). (Pubitemid 40562818)
19. Stiff, T. et al. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64, 2390-2396 (2004). (Pubitemid 38523891)
20. Maira, S.M. et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
21. García-Echeverría, C. et al. In vivo antitumor activity of NVP-AEW541-a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5, 231-239 (2004). (Pubitemid 38402115)
22. Petermann, E., Orta, M.L., Issaeva, N., Schultz, N. & Helleday, T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51- mediated pathways for restart and repair. Mol. Cell 37, 492-502 (2010).
23. Murga, M. et al. A mouse model of ATR-Seckel shows embryonic DNA replicative stress and accelerated ageing. Nat. Genet. 8, 891-898 (2009).
24. Barlow, C. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159-171 (1996). (Pubitemid 26259926)
25. Elson, A. et al. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. USA 93, 13084-13089 (1996). (Pubitemid 26382773)
26. Xu, Y. & Baltimore, D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 10, 2401-2410 (1996). (Pubitemid 26341876)
27. Taccioli, G.E. et al. Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity. Immunity 9, 355-366 (1998). (Pubitemid 28462756)
28. Brown, E.J. & Baltimore, D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14, 397-402 (2000). (Pubitemid 30131885)
29. de Klein, A. et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr. Biol. 10, 479-482 (2000). (Pubitemid 30247338)
30. Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev. 14, 1448-1459 (2000). (Pubitemid 30421838)
31. -/- mice. Genes Dev. 14, 1439-1447 (2000). (Pubitemid 30421837)
32. Syljuåsen, R.G. et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell. Biol. 25, 3553-3562 (2005). (Pubitemid 40559562)
33. Beck, H. et al. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J. Cell Biol. 188, 629-638 (2010).
34. Ruzankina, Y. et al. Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat. Genet. 41, 1144-1149 (2009).
35. Koniaras, K., Cuddihy, A.R., Christopoulos, H., Hogg, A. & O'Connell, M.J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20, 7453-7463 (2001). (Pubitemid 33086904)
36. Ekholm-Reed, S. et al. Deregulation of cyclin E in human cells interferes with prereplication complex assembly. J. Cell Biol. 165, 789-800 (2004). (Pubitemid 38821970)
37. Spruck, C.H., Won, K.A. & Reed, S.I. Deregulated cyclin E induces chromosome instability. Nature 401, 297-300 (1999).
38. Myers, K., Gagou, M.E., Zuazua-Villar, P., Rodriguez, R. & Meuth, M. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress. PLoS Genet. 5, e1000324 (2009).
39. Sidi, S. et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 133, 864-877 (2008). (Pubitemid 351715394)
40. Hickson, I. et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64, 9152-9159 (2004). (Pubitemid 39665530)
41. Willmore, E. et al. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103, 4659-4665 (2004). (Pubitemid 38745999)
42. Nishida, H. et al. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res. 37, 5678-5689 (2009).
43. Konstantinidou, G. et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69, 7644-7652 (2009).
44. Gilad, O. et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 70, 9693-9702 (2010).
45. Bartek, J., Bartkova, J. & Lukas, J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 26, 7773-7779 (2007). (Pubitemid 350242463)
46. Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
47. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
48. Negrini, S., Gorgoulis, V.G. & Halazonetis, T.D. Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220-228 (2010).
49. Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
50. Silva, J.M. et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37, 1281-1288 (2005). (Pubitemid 41568714)